Platelet Transfusion in Dengue-Associated Thrombocytopenia: A Systematic Review and Meta-Analysis.

Authors

Lucca Tamara Alves Carretta, Leonardo Di Cosmo, Lucas Copolillo Faria, Nicole Baptista de Oliveira, Pedro Rodrigues Teixeira, João Vitor Andrade Fernandes, Lara Bourguignon Lopes, Fernando Rocha Oliveira

Published in

Revista da Sociedade Brasileira de Medicina Tropical. Volume 59. Pages e01812026. Epub Aug 03, 2026.

Abstract

Thrombocytopenia is a known and potentially severe manifestation of dengue hemorrhagic fever, raising concerns regarding the risk of hemorrhage. To prevent such complications, prophylactic platelet transfusion (PT) has been suggested as a possible intervention. We aimed to evaluate the efficacy and safety of PT in dengue-associated thrombocytopenia. We conducted a systematic literature search for randomized controlled trials and cohorts across PubMed, Cochrane Library, Web of Science, Scopus, and Embase from inception to November 2025. Primary outcomes were time to platelet count ≥ 50 × 10³ platelets/µL and mortality. Secondary outcomes were bleeding events and length of hospital stay. Risk of bias was assessed using the RoB 2 and ROBINS-I tools. Of 1,900 articles screened, 9 studies were included (6 retrospective cohorts, 2 RCTs, and 1 prospective cohort), comprising 3,377 patients. The PT group included 2,383 patients, whereas the standard supportive care group included 994 patients. PT was not associated with significant reductions in time to platelet recovery (mean difference, 0.73 days; 95% CI: -0.01 to 1.47; I² = 95.9%) or length of hospital stay (mean difference, 0.53 days; 95% CI: -0.15 to 1.22; I² = 96.7%) but was associated with significantly higher risks of mortality (risk ratio, 3.61; 95% CI: 1.12-11.66) and bleeding events (risk ratio, 1. 37; 95% CI: 1.03-1.82). Prophylactic platelet transfusion demonstrated no measurable benefit and was associated with increased mortality and bleeding risk, arguing against its routine use in dengue-associated thrombocytopenia. Evidence was primarily derived from retrospective studies, limiting interpretability and warranting randomized studies.

PMID:
42561330
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.